Compare stocks

Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources: 1. https://inventivapharma.com/en/ 2. https://ir.inventivapharma.com/ 3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.